Free Trial
→ No. You’re not imagining it… (From Porter & Company) (Ad)tc pixel Free SPEC Stock Alerts

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 82 0.00 (0.00%)
As of 03:37 AM Eastern
Compare

SPEC vs. TSTL, BVC, AKR, ODX, and CNSL

Should you buy INSPECS Group stock or one of its competitors? MarketBeat compares INSPECS Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with INSPECS Group include Tristel (TSTL), BATM Advanced Communications (BVC), Akers Biosciences (AKR), Omega Diagnostics Group (ODX), and Cambridge Nutritional Sciences (CNSL). These companies are all part of the "medical instruments & supplies" industry.

How does INSPECS Group compare to Tristel?

INSPECS Group (LON:SPEC) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Tristel has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.43-£4.11M-£8.06N/A
Tristel£49.54M3.68£6.54M£16.2423.45

In the previous week, Tristel had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for Tristel and 0 mentions for INSPECS Group. Tristel's average media sentiment score of 0.75 beat INSPECS Group's score of 0.00 indicating that Tristel is being referred to more favorably in the news media.

Company Overall Sentiment
INSPECS Group Neutral
Tristel Positive

INSPECS Group presently has a consensus price target of GBX 60, suggesting a potential downside of 26.83%. Tristel has a consensus price target of GBX 400, suggesting a potential upside of 5.06%. Given Tristel's higher probable upside, analysts plainly believe Tristel is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

INSPECS Group has a beta of 1.674, indicating that its share price is 67% more volatile than the broader market. Comparatively, Tristel has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

14.8% of INSPECS Group shares are held by institutional investors. Comparatively, 22.0% of Tristel shares are held by institutional investors. 21.0% of INSPECS Group shares are held by company insiders. Comparatively, 21.0% of Tristel shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Tristel 15.88%23.64%9.89%

Summary

Tristel beats INSPECS Group on 12 of the 16 factors compared between the two stocks.

How does INSPECS Group compare to BATM Advanced Communications?

BATM Advanced Communications (LON:BVC) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

INSPECS Group has a net margin of -2.67% compared to BATM Advanced Communications' net margin of -14.90%. INSPECS Group's return on equity of -6.07% beat BATM Advanced Communications' return on equity.

Company Net Margins Return on Equity Return on Assets
BATM Advanced Communications-14.90% -22.13% 0.58%
INSPECS Group -2.67%-6.07%0.45%

In the previous week, BATM Advanced Communications' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
BATM Advanced Communications Neutral
INSPECS Group Neutral

16.9% of BATM Advanced Communications shares are held by institutional investors. Comparatively, 14.8% of INSPECS Group shares are held by institutional investors. 30.4% of BATM Advanced Communications shares are held by insiders. Comparatively, 21.0% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 26.83%. Given INSPECS Group's higher probable upside, analysts plainly believe INSPECS Group is more favorable than BATM Advanced Communications.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BATM Advanced Communications
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

BATM Advanced Communications has a beta of 0.727, meaning that its stock price is 27% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.674, meaning that its stock price is 67% more volatile than the broader market.

BATM Advanced Communications has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than BATM Advanced Communications, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BATM Advanced Communications£123.20M0.38-£278.26K-£4.20N/A
INSPECS Group£191.70M0.43-£4.11M-£8.06N/A

Summary

BATM Advanced Communications and INSPECS Group tied by winning 6 of the 12 factors compared between the two stocks.

How does INSPECS Group compare to Akers Biosciences?

Akers Biosciences (LON:AKR) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

In the previous week, Akers Biosciences' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Akers Biosciences Neutral
INSPECS Group Neutral

14.8% of INSPECS Group shares are held by institutional investors. 21.0% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Akers Biosciences has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Akers Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akers Biosciences£2.32M0.00N/A-£129.60N/A
INSPECS Group£191.70M0.43-£4.11M-£8.06N/A

INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 26.83%. Given Akers Biosciences' higher possible upside, research analysts clearly believe Akers Biosciences is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akers Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Akers Biosciences has a net margin of 0.00% compared to INSPECS Group's net margin of -2.67%. Akers Biosciences' return on equity of 0.00% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Akers BiosciencesN/A N/A N/A
INSPECS Group -2.67%-6.07%0.45%

Summary

INSPECS Group beats Akers Biosciences on 7 of the 11 factors compared between the two stocks.

How does INSPECS Group compare to Omega Diagnostics Group?

INSPECS Group (LON:SPEC) and Omega Diagnostics Group (LON:ODX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Omega Diagnostics Group'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Omega Diagnostics Group Neutral

INSPECS Group has a net margin of -2.67% compared to Omega Diagnostics Group's net margin of -51.15%. INSPECS Group's return on equity of -6.07% beat Omega Diagnostics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Omega Diagnostics Group -51.15%-29.14%-10.53%

INSPECS Group presently has a consensus target price of GBX 60, suggesting a potential downside of 26.83%. Given Omega Diagnostics Group's higher probable upside, analysts clearly believe Omega Diagnostics Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Omega Diagnostics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

14.8% of INSPECS Group shares are held by institutional investors. Comparatively, 29.8% of Omega Diagnostics Group shares are held by institutional investors. 21.0% of INSPECS Group shares are held by insiders. Comparatively, 50.6% of Omega Diagnostics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Omega Diagnostics Group has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Omega Diagnostics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.43-£4.11M-£8.06N/A
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A

INSPECS Group has a beta of 1.674, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Omega Diagnostics Group has a beta of 3.85, meaning that its stock price is 285% more volatile than the broader market.

Summary

INSPECS Group beats Omega Diagnostics Group on 7 of the 13 factors compared between the two stocks.

How does INSPECS Group compare to Cambridge Nutritional Sciences?

INSPECS Group (LON:SPEC) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Cambridge Nutritional Sciences has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.43-£4.11M-£8.06N/A
Cambridge Nutritional Sciences£8.06M0.59-£3.03M£0.603.33

INSPECS Group has a beta of 1.674, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Cambridge Nutritional Sciences has a beta of 2.101, indicating that its stock price is 110% more volatile than the broader market.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Cambridge Nutritional Sciences'average media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Cambridge Nutritional Sciences Neutral

INSPECS Group currently has a consensus target price of GBX 60, indicating a potential downside of 26.83%. Given INSPECS Group's stronger consensus rating and higher possible upside, research analysts plainly believe INSPECS Group is more favorable than Cambridge Nutritional Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cambridge Nutritional Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cambridge Nutritional Sciences has a net margin of 16.94% compared to INSPECS Group's net margin of -2.67%. Cambridge Nutritional Sciences' return on equity of 12.15% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Cambridge Nutritional Sciences 16.94%12.15%-2.36%

14.8% of INSPECS Group shares are held by institutional investors. Comparatively, 1.6% of Cambridge Nutritional Sciences shares are held by institutional investors. 21.0% of INSPECS Group shares are held by insiders. Comparatively, 7.8% of Cambridge Nutritional Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

INSPECS Group and Cambridge Nutritional Sciences tied by winning 7 of the 14 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

Export
MetricINSPECS GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£83.37M£2.99B£6.46B£2.82B
Dividend Yield2.00%2.02%2.76%6.10%
P/E Ratio-10.1716.2220.99365.98
Price / Sales0.4379.85560.3088,162.71
Price / Cash1.63146.5443.4927.89
Price / Book0.822.4610.417.79
Net Income-£4.11M£99.80M£3.57B£5.89B
7 Day PerformanceN/A0.44%6.41%2.38%
1 Month Performance-3.53%3.44%3.55%3.58%
1 Year Performance77.49%-8.04%34.12%79.53%

INSPECS Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
0.6693 of 5 stars		GBX 82
flat		GBX 60
-26.8%		+77.5%£83.37M£191.70MN/A1,673
TSTL
Tristel
1.9536 of 5 stars		GBX 405.16
-2.4%		GBX 400
-1.3%		-1.3%£197.80M£49.54M24.95208
BVC
BATM Advanced Communications
N/AGBX 13.90
-6.1%		N/A-12.8%£47.27M£123.20MN/A980
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32MN/A120
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55MN/A91

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SPEC) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel